Key result
The novel FMD virus lineage A/ASIA/G-18/2019 showed good antigenic match with vaccine candidate A IND 27/2011, while the existing vaccine strain A IND 40/2000 matched only 31% of isolates.
Why the study?
Foot and mouth disease causes large-scale socioeconomic crises, and emerging virus variants originating from endemic Pool 2 in South Asia can spread globally, requiring continuous surveillance.
Observational (n=26)
The emergence of a novel FMD virus lineage in India necessitates updating the vaccine formulation to A IND 27/2011 to ensure adequate antigenic coverage.
May inform FMD surveillance in South Asia; leaves open the role of Pool 2 variants in global emergence.
Foot and mouth disease (FMD) has engendered large scale socioeconomic crises on numerous occasions owing to its extreme contagiousness, transboundary nature, complicated epidemiology, negative impact on productivity, trade embargo, and need for intensive surveillance and expensive control measures. Emerging FMD virus variants have been predicted to have originated and spread from endemic Pool 2, native to South Asia, to other parts of the globe. In this study, 26 Indian serotype A isolates sampled between the year 2015 and 2022 were sequenced for the VP1 region. BLAST and maximum likelihood phylogeny suggest emergence of a novel genetic group within genotype 18, named here as ‘A/ASIA/G-18/2019′ lineage, that is restricted so far only to India and its eastern neighbour, Bangladesh. The lineage subsequent to its first appearance in 2019 seems to have displaced all other prevalent strains, in support of the phenomenon of ‘genotype/lineage turnover’. It has diversified into two distinct sub-clusters, reflecting a phase of active evolution. The rate of evolution of the VP1 region for the Indian serotype A dataset was estimated to be 6.747 × 10−3 substitutions/site/year. India is implementing a vaccination centric FMD control programme. The novel lineage showed good antigenic match with the proposed vaccine candidate A IND 27/2011 when tested in virus neutralization test, while the existing vaccine strain A IND 40/2000 showed homology with only 31% of the isolates. Therefore, in order to combat this challenge of antigenic divergence, A IND 27/2011 could be the preferred strain in the Indian vaccine formulations.
No takes yet. Share an insight, caveat, or question.
Mohapatra et al. (2023) conducted an observational in Foot and mouth disease (FMD) (n=26). Vaccine candidate A IND 27/2011 vs. Vaccine strain A IND 40/2000 was evaluated on Antigenic match in virus neutralization test. The novel FMD virus lineage A/ASIA/G-18/2019 showed good antigenic match with vaccine candidate A IND 27/2011, while the existing vaccine strain A IND 40/2000 matched only 31% of isolates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: